tarenflurbil (Flurizan, R-flurbiprofen)
Jump to navigation
Jump to search
Introduction
Not FDA-approved.
Indications
- Alzheimer's disease (not effective, but then what is?)[1]
Dosage
Adverse effects
- small increase in dizziness, anemia, & infections relative to placebo
- increased risk of pneumonia, Herpes zoster
Mechanism of action
- enantiomer of flurbiprofen with clinically insignificant anti-inflammatory activity
- influences the production of amyloid via through the formation of shorter, less-toxic chains (selective Abeta42-lowering agent)
- does not slow cognitive decline or the loss of activities of daily living in patients with mild Alzheimer's disease
More general terms
References
- ↑ 1.0 1.1 Green RC et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA 2009 Dec 16; 302:2557. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20009055
Montine TJ and Larson EB. Late-life dementias: Does this unyielding global challenge require a broader view? JAMA 2009 Dec 16; 302:2593. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20009062